Global Medical Asparaginase market will reach 440 million US$ by the end of 2025 www.qyresearch.com
Contact
Beijing Hengzhou Bozhi International Information Consulting Web: www.qyresearch.com
TEL:+86-13660489419, Office:+86-2022093278 Media: press@qyresearch.com Marketing: sales@qyresearchglobal.com www.qyresearch.com
Facebook: @QYResearchOfficial ,Twitter: @QYResearch_ Wechat Official Account: QYResearch, Weibo: 恒州博智
QYResearch
• Asparaginase is an enzyme, as a medication it is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and nonHodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available.
• Asparaginase was approved for medical use in the United States in 1978. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.
www.qyresearch.com
QYResearch
• The classification of Medical Asparaginase includes Escherichia coli, Erwinia Chrysanthemi and Pegylated, and the sales proportion of Escherichia coli in 2017 is about 64.6%, and the proportion is decreasing trend from 2013 to 2018.
• Medical Asparaginase is widely sales for Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia and Others. The most proportion of Medical Asparaginase is sales in Acute Lymphoblastic Leukemia, and the consumption proportion is about 90% in 2017. www.qyresearch.com
QYResearch
• North America is the largest consumption place, with a revenue market share nearly 53.5% in 2017. Following North America, Europe is the second largest consumption place with the revenue market share of 37.2%, China is also an important sales region for the Medical Asparaginase, In China, the price is lower than the developed countries.
www.qyresearch.com
QYResearch
• Market competition is intense. Jazz Pharmaceuticals, Shire, Medac GmbH, Kyowa Hakko Kirin, etc. are the leaders of the industry. They hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.
www.qyresearch.com
QYResearch The global Medical Asparaginase market is valued at 390 million US$ in 2017 and will reach 440 million US$ by the end of 2025, growing at a CAGR of 1.4% during 2018-2025.
Click to view the full report: https://www.qyresearch.com/index/detail/265838/globalmedical-asparaginase-sales-market
www.qyresearch.com